Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program
Introduction. Olaparib is the only PARP inhibitor approved in Russia for the maintenance therapy for BRCA-positive ovarian cancer after frontline chemotherapy. We conducted a real-world analysis of olaparib efficacy and safety for this indication.Aim. To assess the efficacy of PARP inhibitors in real-world clinical practice.Materials and methods. Patients with stage III-IV BRCA-mutated ovarian cancer who received olaparib maintenance therapy in expanded access program in 03.2019-12.2020 timeframe. Briefly, key inclusion criteria were: serous or endometrioid highgrade ovarian cancer; pathogenic BRCA1/2 mutation; primary or interval debulking; complete or partial response to frontline platinum-based therapy. Olaparib was administered as tablets (300 mg BID) up to 2-years, disease progression or unacceptable toxicity, whichever occurred first. The primary endpoint of the study was progression-free survival (PFS), overall survival (OS) and safety were key secondary endpoints. Statistical analysis was done with R and RStudio software.Results and discussion. 23 patients were enrolled. Median age was 49 years, all patients had high-grade serous adenocarcinoma histology. Complete debulking at primary or interval surgery was achieved in 30% of patients. With median follow-up time equal to 22 months, median PFS and OS were not reached. The 2-year PFS and OS were 65 and 84%, respectively. Grade 3-4 adverse events was detected in 7 (30.4%) patients.Conclusion. Our results supports high efficacy of olaparib in real clinical practice setting reported in the SOLO1 trial..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Медицинский совет - (2022), 9, Seite 77-83 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
A. A. Rumyantsev [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Brca |
|---|
| doi: |
10.21518/2079-701X-2022-16-9-77-83 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ033741891 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ033741891 | ||
| 003 | DE-627 | ||
| 005 | 20230505014215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2022-16-9-77-83 |2 doi | |
| 035 | |a (DE-627)DOAJ033741891 | ||
| 035 | |a (DE-599)DOAJbfaddd974a224ac8b80f777641cf367f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a A. A. Rumyantsev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction. Olaparib is the only PARP inhibitor approved in Russia for the maintenance therapy for BRCA-positive ovarian cancer after frontline chemotherapy. We conducted a real-world analysis of olaparib efficacy and safety for this indication.Aim. To assess the efficacy of PARP inhibitors in real-world clinical practice.Materials and methods. Patients with stage III-IV BRCA-mutated ovarian cancer who received olaparib maintenance therapy in expanded access program in 03.2019-12.2020 timeframe. Briefly, key inclusion criteria were: serous or endometrioid highgrade ovarian cancer; pathogenic BRCA1/2 mutation; primary or interval debulking; complete or partial response to frontline platinum-based therapy. Olaparib was administered as tablets (300 mg BID) up to 2-years, disease progression or unacceptable toxicity, whichever occurred first. The primary endpoint of the study was progression-free survival (PFS), overall survival (OS) and safety were key secondary endpoints. Statistical analysis was done with R and RStudio software.Results and discussion. 23 patients were enrolled. Median age was 49 years, all patients had high-grade serous adenocarcinoma histology. Complete debulking at primary or interval surgery was achieved in 30% of patients. With median follow-up time equal to 22 months, median PFS and OS were not reached. The 2-year PFS and OS were 65 and 84%, respectively. Grade 3-4 adverse events was detected in 7 (30.4%) patients.Conclusion. Our results supports high efficacy of olaparib in real clinical practice setting reported in the SOLO1 trial. | ||
| 650 | 4 | |a olaparib | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a brca | |
| 650 | 4 | |a maintenance therapy | |
| 650 | 4 | |a parp inhibitors | |
| 650 | 4 | |a clinical practice | |
| 650 | 4 | |a real-world evidence (rwe) | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a A. S. Tyulyandina |e verfasserin |4 aut | |
| 700 | 0 | |a I. A. Pokataev |e verfasserin |4 aut | |
| 700 | 0 | |a E. R. Israelyan |e verfasserin |4 aut | |
| 700 | 0 | |a M. Е. Abramov |e verfasserin |4 aut | |
| 700 | 0 | |a H. N. Lud |e verfasserin |4 aut | |
| 700 | 0 | |a S. A. Tyulyandin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2022), 9, Seite 77-83 |w (DE-627)DOAJ000029483 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g number:9 |g pages:77-83 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2022-16-9-77-83 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/bfaddd974a224ac8b80f777641cf367f |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/6919 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2022 |e 9 |h 77-83 | ||